Boston Scientific expects to nearly double Target Therapeutics revenues in 1997, CFO says.
This article was originally published in The Gray Sheet
Executive Summary
BOSTON SCIENTIFIC TO NEARLY DOUBLE TARGET THERAPEUTICS REVENUE to "over $170 mil." in 1997, Chief Financial Officer Larry Best predicted June 17 at the Piper Jaffray investment conference in Minneapolis. BSC expects that its newly acquired minimally invasive neurointerventional division, which generated an estimated $89.2 mil. in sales during fiscal year 1997 (ended March 31) as an independent company, will benefit from an ongoing switch to direct sales in international markets.